Skip to main content

Table 1 Baseline Characteristics of Patients with stage IIIA pN2 status NSCLC

From: Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number

  Baseline Characteristics of Patients in OS analysis Baseline Characteristics of Patients in LCSS analysis
  No.(%) of Patients (n = 3377)   No.(%) of Patients (n = 3077)  
Demographic No Port (n = 2179) Port (n = 1198) P Value for χ2 No Port (n = 1983) Port (n = 1094) P Value for χ2
Age at diagnosis, years
  < 65 887 (40.7%) 619 (51.7%) <0.001 829(41.8%) 573(52.4%) <0.001
  ≥ 65 1292 (59.3%) 579 (48.3%)   1154(58.2%) 521(47.6%)  
Sex
 Male 1108 (50.4%) 605 (50.5%) 0.846 996(50.2%) 539(49.3%) 0.611
 Female 1071 (49.6%) 593 (49.5%)   987(49.8%) 555(50.7%)  
Race
 White 1789 (82.1%) 967 (80.7%) 0.564 1624(81.9%) 882(80.6%) 0.622
 Black 209 (9.6%) 120 (10.0%)   193(9.7%) 110(10.1%)  
 Other 181 (8.3%) 111 (9.3%)   166(8.4%) 102(9.3%)  
Location
 Main bronchus 28 (1.3%) 14 (1.2%) 0.106 27(1.4%) 11(1.0%) 0.186
 Upper lobe 1221 (56.0%) 728 (60.8%)   1116(56.3%) 663(60.6%)  
 Middle lobe 102 (4.7%) 56 (4.7%)   93(4.7%) 52(4.8%)  
 Lower lobe 760 (34.9%) 366 (30.5%)   683(34.4%) 336(30.7%)  
 Overlapping/lung, NOS 68 (3.1%) 34 (2.8%)   64(3.2%) 32(2.9%)  
Tumor size, cm
  ≤ 3.0 939 (43.1%) 507 (42.3%) 0.805 849(42.8%) 464(42.4%) 0.73
 3.1 to 5.0 711 (32.6%) 402 (33.6%)   645(32.5%) 370(33.8%)  
 5.1 to 7.0 323 (14.8%) 168 (14.0%)   301(15.2%) 153(14.0%)  
  ≥ 7.1 161 (7.4%) 99 (8.3%)   144(7.3%) 87(8.0%)  
 Unknown 45 (2.1%) 22 (1.8%)   44(2.2%) 20(1.8%)  
T stage
 T1 611 (28.0%) 326 (27.2%) 0.155 550(27.7%) 299(27.3%) 0.355
 T2 1305 (59.9%) 701 (58.5%)   1181(59.6%) 638(58.3%)  
 T3 244 (11.2%) 164 (13.7%)   233(11.7%) 150(13.7%)  
 TX 19 (0.9%) 7 (0.6%)   19(1.0%) 7(0.7%)  
Laterality
 Right 1206 (55.3%) 687 (57.4%) 0.241 1101(55.5%) 640(58.6%) 0.098
 Left 973 (44.7%) 509 (42.6%)   882(44.5%) 452(41.4%)  
 Unspecified / 2   / 2  
Histology
 Non-small cell carcinoma 141 (6.5%) 81 (6.8%) 0.113 128(6.5%) 71(6.5%) 0.076
 Adenocarcinoma, NOS 1366 (62.7%) 795 (66.4%)   1251(63.1%) 738(67.4%)  
 Squamous cell carcinoma, NOS 609 (27.9&) 294 (24.5%)   546(27.5%) 259(23.7%)  
 Large cell carcinoma, NOS 63 (2.9%) 28 (2.3%)   58(2.9%) 26(2.4%)  
Surgery type
 Lobectomy 1894 (86.9%) 1087 (90.7%) 0.001 1719(86.7%) 999(91.3%) <0.001
 Pneumonectomy 285 (13.1%) 111 (9.3%)   264(13.3%) 95(8.7%)  
Number of positive lymph nodes
 1 655 (30.1%) 286(23.9%) <0.001 588(29.7%) 263(24.1%) 0.009
 2 426 (19.6%) 212(17.7%)   386(19.5%) 194(17.7%)  
 3 278 (12.8%) 173(14.4%)   253(12.8%) 156(14.3%)  
 4 198 (9.1%) 116(9.7%)   183(9.2%) 103(9.4%)  
 5 135 (6.2%) 103(8.6%)   124(6.3%) 96(8.8%)  
 6 101 (4.6%) 59(4.9%)   92(4.6%) 54(4.9%)  
 7 62(2.8%) 41(3.4%)   56(2.8%) 35(3.2%)  
  ≥ 8 200(9.2%) 138(11.5%)   187(9.4%) 127(11.6%)  
 No. of unspecified 124(5.9%) 70(5.9%)   114(5.7%) 66(6.0%)  
Number of positive lymph nodes
  ≤ 3 1359 (66.1%) 671 (59.5%) <0.001 1227 (65.7%) 613 (59.6%) 0.001
  > 3 (Unspecified Excluded) 696 (33.9%) 457 (40.5%)   642 (34.3%) 415 (40.4%)  
  1. Abbreviations: NSCLC non-small cell lung cancer, OS overall survival, LCSS lung cancer-specific survival, NOS not otherwise specified